383
Participants
Start Date
March 4, 2005
Primary Completion Date
March 27, 2006
Study Completion Date
March 27, 2006
HPV 16/18 L1 AS04
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 1
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 2
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 3
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 4
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 5
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
HPV-16/18/31/45 L1 AS04 Formulation 6
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
GSK Investigational Site, Brussels
GSK Investigational Site, Wilrijk
GSK Investigational Site, Leuven
GSK Investigational Site, Liège
GSK Investigational Site, Roeselare
GSK Investigational Site, Ghent
GSK Investigational Site, Aurora
GSK Investigational Site, Golden
GSK Investigational Site, Salt Lake City
GSK Investigational Site, Salt Lake City
GSK Investigational Site, Kingston
Lead Sponsor
GlaxoSmithKline
INDUSTRY